首页> 外文OA文献 >Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

【2h】

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

机译：新辅助二甲双胍联合来曲唑与安慰剂联合来曲唑治疗雌激素受体阳性绝经后乳腺癌（METEOR）的II期随机试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jisun Kim; Woosung Lim; Eun-Kyu Kim; Min-Kyoon Kim; Nam-Sun Paik; Sang-Seol Jeong; Jung-han Yoon; Chan Heun Park; Sei Hyun Ahn; Lee Su Kim; Sehwan Han; Seok Jin Nam; Han-Sung Kang; Seung Il Kim; Young Bum Yoo; Joon Jeong; Tae Hyun Kim; Taewoo Kang; Sung-Won Kim; Yongsik Jung; Jeong Eon Lee; Ku Sang Kim; Jong-Han Yu; Byung Joo Chae; So-Youn Jung; Eunyoung Kang; Su Yun Choi; Hyeong-Gon Moon; Dong-Young Noh; Wonshik Han;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) [J] . Jisun Kim, Woosung Lim, Eun-Kyu Kim, BMC Cancer . 2014,第1期

机译：新辅助二甲双胍联合来曲唑与安慰剂联合来曲唑治疗雌激素受体阳性绝经后乳腺癌（METEOR）的II期随机试验
2. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. [J] . Baselga J, Semiglazov V, van Dam P, Journal of Clinical Oncology . 2009,第16期

机译：雌激素受体阳性乳腺癌患者新辅助依维莫司加来曲唑与安慰剂加来曲唑比较的II期随机研究。
3. TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J] . Saura Cristina, Hlauschek Dominik, Oliveira Mafalda, The lancet oncology . 2019,第9期

机译：TeNeoadjuvant Letrozole Plus Taselisib与Letrowzole Plus Placebo在绝经后患者患有雌激素受体阳性，Her2阴性，早期乳腺癌（Lorelei）：多方形，随机，双盲，安慰剂控制，第2期试验
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) [O] . Jisun Kim, Woosung Lim, Eun-Kyu Kim, 2014

机译：新辅助二甲双胍联合来曲唑与安慰剂联合来曲唑治疗雌激素受体阳性绝经后乳腺癌（METEOR）的II期随机试验
7. Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer [O] . Guarneri Valentina, Generali Daniele, Frassoldati Antonio, 2014

机译：来曲唑-拉帕替尼治疗绝经后激素受体阳性，人表皮生长因子受体2-阴性，可手术的乳腺癌的双盲，安慰剂对照，随机，IIB期新辅助研究

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

著录项

引文网络

相似文献

相关主题

期刊订阅